公开(公告)号：WO2021191688A1

公开(公告)日：2021-09-30

申请号：PCT/IB2021/000231

申请日：2021-03-26

申请人： INSTITUT PASTEUR

发明人： VIGNUZZI, Marco ,  MEYER, Björn ,  REZELJ, Veronica ,  LEVI, Laura ,  BERNHAUEROVA, Veronika ,  VALLET, Thomas ,  PIEPLU, Tanguy ,  SHENGJULER, Djoshkun ,  BEAUCOURT, Stéphanie ,  BLANC, Hervé ,  PARDIGON, Nathalie ,  BARBA-SPAETH, Giovanna ,  SALEH, Maria-Carla

IPC分类号： C12N7/00 ,  A61K39/00 ,  C12N2770/20021 ,  C12N2770/20034 ,  C12N2770/24021 ,  C12N2770/24034 ,  C12N2770/32321 ,  C12N2770/32334 ,  C12N2770/32721 ,  C12N2770/32734 ,  C12N2770/36121 ,  C12N2770/36134

摘要： Method for producing a defective interfering viral genome (DVG), defective interfering particles comprising the DVG, and methods and uses thereof.

公开(公告)号：WO2023279042A2

公开(公告)日：2023-01-05

申请号：PCT/US2022/073285

申请日：2022-06-30

申请人： SIEMENS HEALTHCARE LABORATORY, LLC

发明人： PHILIPP, Isabelle ,  LEE, Wing-Sum

IPC分类号： C12Q1/70 ,  C12N15/11 ,  C12Q1/6888 ,  C12N2770/20021 ,  C12N7/00 ,  C12Q1/6869 ,  C12Q1/6886 ,  C12Q2600/156

摘要： The present disclosure describes the design and characterization of genomic assays for detecting SARS CoV-2 variants. The present disclosure provides compositions and methods associated with such assays.

公开(公告)号：WO2021254341A1

公开(公告)日：2021-12-23

申请号：PCT/CN2021/100164

申请日：2021-06-15

申请人： 睿丰康生物医药科技（浙江）有限公司

发明人： 秦晓峰 ,  韦治明 ,  龙丽梅 ,  杨仁祥 ,  李帆

IPC分类号： C12N7/01 ,  C12N15/40 ,  C12N5/10 ,  C12N15/867 ,  C12N15/65 ,  G01N33/569 ,  C07K14/005 ,  C12N15/86 ,  C12N2740/15043 ,  C12N2760/20221 ,  C12N2770/20021 ,  C12N2770/20022 ,  C12N7/00 ,  G01N33/56983

摘要： 提供一种冠状病毒假病毒的包装系统，包括Fluc、EGFP双报告基因置换GP基因的水泡性口炎病毒VSV载体、表达冠状病毒刺突蛋白S的装配细胞；该包装系统采用一步法包装方法可快速包装出假病毒，可用于COVID‐19(SARS‐CoV‐2)、SARS(SARS‐CoV)、MERS等冠状病毒及其他病毒的研究，还可用于通过病毒污染分布模型、搭建场景、取样检测的步骤的评估消杀剂效力。

公开(公告)号：WO2021231503A2

公开(公告)日：2021-11-18

申请号：PCT/US2021/031876

申请日：2021-05-11

申请人： THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY

发明人： BARNA, Maria ,  LEPPEK, Kathrin

IPC分类号： A61K48/00 ,  C12N5/10 ,  C12N15/82 ,  C12N15/67 ,  C12N2770/20021 ,  C12N2840/105 ,  C12N7/00

摘要： Systems, methods, and kits for enhancing mRNA translation are disclosed. Some embodiments describe expression constructs for producing a peptide and include a translational enhancer. Additional embodiments describe methods for producing a peptide using a construct including a translational enhancer. Certain embodiments further enhance mRNA stability.

公开(公告)号：WO2022072215A2

公开(公告)日：2022-04-07

申请号：PCT/US2021/051807

申请日：2021-09-23

申请人： ZOETIS SERVICES LLC

发明人： RUAN, Xiaosai ,  LIU, Can ,  LI, Haiyan ,  YU, Hongxin

IPC分类号： A61K39/215 ,  C12N7/00 ,  A61K2039/5254 ,  A61K2039/542 ,  A61K2039/552 ,  A61K39/12 ,  C12N2770/20021 ,  C12N2770/20022 ,  C12N2770/20034 ,  C12N2770/20062

摘要： The disclosure provides a C -terminally truncated Spike protein of PEDV. Nucleic acid sequences including same and a virus comprising same, as well as methods of use are also provided.

公开(公告)号：WO2021257841A1

公开(公告)日：2021-12-23

申请号：PCT/US2021/037846

申请日：2021-06-17

申请人： MEISSA VACCINES, INC.

发明人： MOORE, Martin ,  JORDAN, Robert ,  TIONI, Mariana

IPC分类号： A61K39/215 ,  C07K14/135 ,  C07K14/165 ,  A61K2039/5254 ,  A61K2039/5256 ,  A61K2039/541 ,  A61K2039/543 ,  A61K2039/57 ,  A61K2039/575 ,  A61K39/12 ,  A61P31/14 ,  C12N2760/18541 ,  C12N2770/20021 ,  C12N2770/20034

摘要： The invention relates generally to chimeric viral fusion proteins comprising the ectodomain and optionally the transmembrane domain of a first viral fusion protein ( e.g., a spike protein of a coronavirus) and the cytoplasmic domain of a second viral fusion protein (e.g. RSV), immunogenic compositions comprising such chimeric proteins, and methods of use of same.

公开(公告)号：WO2021252821A1

公开(公告)日：2021-12-16

申请号：PCT/US2021/036897

申请日：2021-06-11

申请人： MBF THERAPEUTICS INC.

发明人： KELLER, Lorraine ,  PADIDAM, Malla

IPC分类号： A61K39/00 ,  A61K39/12 ,  A61K39/39 ,  A61K2039/53 ,  A61K2039/552 ,  A61K2039/572 ,  A61K2039/575 ,  A61K2039/80 ,  A61P35/00 ,  C07K14/005 ,  C07K14/70539 ,  C07K2319/00 ,  C07K2319/40 ,  C07K2319/70 ,  C12N2710/10343 ,  C12N2710/12022 ,  C12N2710/12034 ,  C12N2710/16021 ,  C12N2710/16622 ,  C12N2710/16634 ,  C12N2710/16722 ,  C12N2710/16734 ,  C12N2750/10022 ,  C12N2760/16121 ,  C12N2760/16122 ,  C12N2760/16134 ,  C12N2770/10022 ,  C12N2770/10034 ,  C12N2770/20021 ,  C12N2770/20022 ,  C12N2770/20034

摘要： Provided are pharmaceutical/veterinary compositions including (1) an effective amount of nucleic acid molecule(s) comprising nucleotide sequences encoding (a) disease-causing agent-associated antigen(s) and (b) innate trained immunity immunomodulator(s), and (2) an effective amount of either (a) calcium phosphate nanoparticles associated with the molecules that detectably enhance cellular uptake of the molecules, immunogenicity of the composition, or both, or (b) a nonpathogenic bacterial vector that contains the molecules and detectably promotes delivery of the nucleic acid molecules. Immunomodulators can include signal transducing activator protein sequences, antigen(s) can include immune cell targeting sequences (e.g., alphaherpesvirus glycoprotein D sequences) or internal targeting sequences (such as polyubiquitin sequences), and expression products can include checkpoint inhibitors. Provided also are methods of using compositions to treat or prevent diseases in humans or livestock/companion animals, including viral diseases and cancers.

公开(公告)号：WO2022226423A2

公开(公告)日：2022-10-27

申请号：PCT/US2022/026223

申请日：2022-04-25

申请人： THE J. DAVID GLADSTONE INSTITUTES, A TESTAMENTARY TRUST ESTABLISHED UNDER THE WILL OF J. DAVID GLADSTONE ,  RODICK, Robert

发明人： WEINBERGER, Leor S. ,  CHATURVEDI, Sonali

IPC分类号： A61P31/14 ,  C07K14/005 ,  C12N15/11 ,  C12N15/1058 ,  C12N15/1065 ,  C12N15/1131 ,  C12N15/86 ,  C12N2310/11 ,  C12N2770/20021 ,  C12N2770/20022 ,  C12N2770/20032 ,  C12N7/00 ,  C40B40/02

摘要： Described herein are compositions of recombinant SARS-CoV-2 constructs and particles that can interfere with or block infection of uninfected cells. The compositions and methods described herein are useful for treatment of SARS-Co V-2 infections. The recombinant SARS-CoV-2 construct cannot replicate by itself, but can replicate in the presence of infective SARS-CoV-2 (e.g., replication competent SARS-CoV-2). Thus, the present application in one aspect provides a recombinant SARS-Co V-2 construct (e.g., SARS-CoV-2 TIP) capable of interfering with SARS-CoV-2 replication, wherein the recombinant SARS-CoV-2 construct cannot replicate by itself, and wherein the recombinant SARS-CoV-2 construct can replicate in the presence of SARS-CoV-2.

公开(公告)号：WO2022011428A1

公开(公告)日：2022-01-20

申请号：PCT/AU2021/050763

申请日：2021-07-16

申请人： GRIFFITH UNIVERSITY ,  INDIAN IMMUNOLOGICALS LIMITED

发明人： MAHALINGAM, Surendran ,  MERITS, Andres ,  LIU, Xiang

IPC分类号： A61K39/12 ,  C12N7/00 ,  C12N7/04 ,  A61K2039/5254 ,  A61K39/215 ,  A61P31/14 ,  C12N2770/20021 ,  C12N2770/20034 ,  C12N2770/20062

摘要： This invention relates to a codon deoptimized severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) genome. In particular, embodiments of the invention concern a vaccine comprising live attenuated SARS-CoV-2 comprising a partly codon deoptimized viral genome, SARS-CoV-2 comprising a partly codon deoptimized viral genome, as well as their use in methods of treatment and prevention of viral infection. The ORF1a region of the viral genome has been codon deoptimized.

公开(公告)号：WO2021237174A1

公开(公告)日：2021-11-25

申请号：PCT/US2021/033776

申请日：2021-05-21

申请人： VAXESS TECHNOLOGIES, INC.

发明人： SCHRADER, Michael, A. ,  KOSUDA, Kathryn, M. ,  KLUGE, Jonathan, A. ,  CIRELLI, Kimberly, M. ,  BORKOWSKI, Emily, L. ,  CAUDILL, Cassie, L. ,  DIRCKX, Matthew ,  HARTMAN, Nickolas, W. ,  VALENTI, Livio

IPC分类号： A61K9/00 ,  A61K39/215 ,  C12N7/00 ,  C12N15/86 ,  A61K2039/54 ,  A61K2039/575 ,  A61K39/12 ,  A61K9/0021 ,  C07K14/005 ,  C12N2760/16022 ,  C12N2760/16023 ,  C12N2760/16034 ,  C12N2770/20021 ,  C12N2770/20022 ,  C12N2770/20023 ,  C12N2770/20034

摘要： Microneedle and microneedle devices including implantable tips (e.g., silk-based tips) for sustained dermal delivery of a coronavirus and/or influenza vaccine, kits, as well as methods of manufacturing and using the same are described herein. In other embodiments, compositions and methods for controlled- or sustained-administration of a coronavirus vaccine and/or an influenza vaccine to provide improved immunogenicity and/or broad-spectrum immunity to a subject are also described.